Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Atsushi Kuwahara, Misae Nazuka, Yuri Kuroki, Kohei Ito, Shunsuke Watanabe, Izumi Kumagai & Ryutaro Asano. (2023) Functional integration of protein A binding ability to antibody fragments for convenient and tag-free purification. Bioengineered 14:1.
Read now
Read now
Yining Zhao, Yumei Li, Xiaoqiong Wu, Li Li, Jiayu Liu, Yanlan Wang, Yue Liu, Qing Li & Zhong Wang. (2020) Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies. Cancer Biology & Therapy 21:1, pages 72-80.
Read now
Read now
Richard Burt, Dana Warcel & Adele K. Fielding. (2019) Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. Human Vaccines & Immunotherapeutics 15:3, pages 594-602.
Read now
Read now
Kum Ja Lee, Vivian Chow, Ashley Weissman, Sunil Tulpule, Ibrahim Aldoss & Mojtaba Akhtari. (2016) Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults. Therapeutics and Clinical Risk Management 12, pages 1301-1310.
Read now
Read now
Articles from other publishers (21)
Jun Fang, Shifa Lai, Haoyang Yu & Lan Ma. (2023) Suppression of MUC1-Overexpressing Tumors by a Novel MUC1/CD3 Bispecific Antibody. Antibodies 12:3, pages 47.
Crossref
Crossref
Sepideh Razi & Nima Rezaei. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
27
.
Yaping Sun & Jian Xu. (2022) Emerging Antibodies in Cancer Therapy. Advanced NanoBiomed Research 3:1.
Crossref
Crossref
Pauline Mocquot, Yasmine Mossazadeh, Léopoldine Lapierre, Fanny Pineau & Fabien Despas. (2022) The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials. Journal of Clinical Pharmacy and Therapeutics 47:9, pages 1337-1351.
Crossref
Crossref
Srushti Mahajan, Mayur Aalhate, Santosh Kumar Guru & Pankaj Kumar Singh. (2022) Nanomedicine as a magic bullet for combating lymphoma. Journal of Controlled Release 347, pages 211-236.
Crossref
Crossref
Essam A Tawfik, Norah A Aldrak, Shahad H Albrahim, Dunia A Alzahrani, Haya A Alfassam, Samar M Alkoblan, Abdulaziz M Almalik, Kok-Siong Chen, Rana Abou-Khalil, Khalid Shah & Nada M Zaidan. (2021) Immunotherapy in hematological malignancies: recent advances and open questions. Immunotherapy 13:14, pages 1215-1229.
Crossref
Crossref
Alison Betts, Nahor Haddish-Berhane, Dhaval K. Shah, Piet H. van der Graaf, Frank Barletta, Lindsay King, Tracey Clark, Cris Kamperschroer, Adam Root, Andrea Hooper & Xiaoying Chen. (2019) A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®. The AAPS Journal 21:4.
Crossref
Crossref
Stanton Goldman & Jessica Hochberg. 2019. Non-Hodgkin's Lymphoma in Childhood and Adolescence. Non-Hodgkin's Lymphoma in Childhood and Adolescence
295
304
.
Archana Thakur, Manley Huang & Lawrence G. Lum. (2018) Bispecific antibody based therapeutics: Strengths and challenges. Blood Reviews 32:4, pages 339-347.
Crossref
Crossref
Limin Lin, Li Li, Changhua Zhou, Jing Li, Jiayu Liu, Rui Shu, Bin Dong, Qing Li & Zhong Wang. (2018) A HER2 bispecific antibody can be efficiently expressed in Escherichia�coli with potent cytotoxicity. Oncology Letters.
Crossref
Crossref
Yumei Li, Changhua Zhou, Jing Li, Jiayu Liu, Limin Lin, Li Li, Donglin Cao, Qing Li & Zhong Wang. (2018) Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells. PLOS ONE 13:1, pages e0191024.
Crossref
Crossref
Matthew J. Barth, Jessica Hochberg, Nader Kim El-Mallawany & Mitchell S. Cairo. 2018. Immunotherapy for Pediatric Malignancies. Immunotherapy for Pediatric Malignancies
79
116
.
Maureen C. Ryan, Maria Corinna Palanca-Wessels, Brian Schimpf, Kristine A. Gordon, Heather Kostner, Brad Meyer, Changpu Yu, Heather A. Van Epps & Dennis Benjamin. (2017) Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies. Blood 130:18, pages 2018-2026.
Crossref
Crossref
MeiQi May Liau, Valencia Long, Jingxiang Huang & Huma Jaffar. (2017) Blinatumomab-associated vasculitis. JAAD Case Reports 3:5, pages 395-397.
Crossref
Crossref
T. Noelle Lombana & Christoph Spiess. 2017. Analytical Characterization of Biotherapeutics. Analytical Characterization of Biotherapeutics
169
198
.
Matthew Ku, Geoff Chong & Eliza A. Hawkes. (2017) Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab. Blood Reviews 31:1, pages 23-35.
Crossref
Crossref
M Pizzi, M Boi, F Bertoni & G Inghirami. (2016) Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. Leukemia 30:9, pages 1805-1815.
Crossref
Crossref
Francesca Ferrari, Stefania Bellone, Jonathan Black, Carlton L. Schwab, Salvatore Lopez, Emiliano Cocco, Elena Bonazzoli, Federica Predolini, Gulden Menderes, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Peter E. Schwartz & Alessandro D. Santin. (2015) Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. Journal of Experimental & Clinical Cancer Research 34:1.
Crossref
Crossref
Jingjing Wu, Jiaping Fu, Mingzhi Zhang & Delong Liu. (2015) Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. Journal of Hematology & Oncology 8:1.
Crossref
Crossref
Yu-Tzu Tai & Kenneth C Anderson. (2015) Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy 7:11, pages 1187-1199.
Crossref
Crossref
Felipe Vences-Catalán, Chiung-Chi Kuo & Shoshana Levy. (2015) Role of an arginine–lysine rich motif in maturation and trafficking of CD19. Biochemical and Biophysical Research Communications 465:3, pages 319-323.
Crossref
Crossref